Description
Human CHP Protein
| Catalog number: | B2011948 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 g |
| Molecular Weight or Concentration: | 1 mg/mL |
| Supplied as: | Solution |
| Applications: | molecular tool for various biochemical applications |
| Storage: | -20 C |
| Keywords: | Calcium binding protein CHP protein, Calcineurin B homolog protein, Sid470 protein, SLC9A1 binding protein protein, SLC9A1BP protein, Wrch2, Calcium-binding protein p22 protein, Calcineurin homologous protein protein, Sid 470 protein |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Pellegrini L, Bonfio C, Chadwick J, Begum F, Skehel M, Lancaster MA. Human CNS barrier-forming organoids with cerebrospinal fluid production Science. 2020 Jul 10;369(6500):eaaz5626.
- Witchel SF. Congenital Adrenal Hyperplasia J Pediatr Adolesc Gynecol. 2017 Oct;30(5):520-534.
- Haag A, Walser M, Henggeler A, Hajnal A. The CHORD protein CHP-1 regulates EGF receptor trafficking and signaling in C. elegans and in human cells Elife. 2020 Feb 13;9:e50986.
- Yin C, Ackermann S, Ma Z, Mohanta SK, Zhang C, Li Y, Nietzsche S, Westermann M, Peng L, Hu D, Bontha SV, Srikakulapu P, Beer M, Megens RTA, Steffens S, Hildner M, Halder LD, Eckstein HH, Pelisek J, Herms J, Roeber S, Arzberger T, Borodovsky A, Habenicht L, Binder CJ, Weber C, Zipfel PF, Skerka C, Habenicht AJR. ApoE attenuates unresolvable inflammation by complex formation with activated C1q Nat Med. 2019 Mar;25(3):496-506.
- Horwitz S, OConnor OA, Pro B, Trmper L, Iyer S, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Menne T, Belada D, Ills , Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Httmann A, Savage KJ, Yuen S, Zinzani PL, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Illidge T. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma Ann Oncol. 2022 Mar;33(3):288-298.
- Bourbon E, Salles G. Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma Expert Opin Investig Drugs. 2020 Oct;29(10):1079-1088.
- Pease D, Scheckel C, Schaper E, Eckhardt V, Emmenegger M, Xenarios I, Aguzzi A. Genome-wide identification of microRNAs regulating the human prion protein Brain Pathol. 2019 Mar;29(2):232-244.
- Svoboda J, Bair SM, Landsburg DJ, Dwivedy Nasta S, Nagle SJ, Barta SK, Khan N, Filicko-OHara J, Gaballa S, Strelec L, Chong E, Mitnick S, Waite TS, King C, Ballard H, Youngman M, Gerson J, Plastaras JP, Maity A, Bogusz AM, Hung SS, Nakamura H, Nejati R, Steidl C, Lim M, Ruella M, Schuster SJ. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas Haematologica. 2021 Jun 1;106(6):1705-1713.
- Dieli-Conwright CM, Parmentier JH, Sami N, Lee K, Spicer D, Mack WJ, Sattler F, Mittelman SD. Adipose tissue inflammation in breast cancer survivors: effects of a 16-week combined aerobic and resistance exercise training intervention Breast Cancer Res Treat. 2018 Feb;168(1):147-157.
